adalimumab vs Hemay007
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00055497 · Phase 3 · completed
Design meets top-tier criteria (randomized, quadruple-blind, placebo-controlled, hard clinical endpoint), but the randomized comparison population was very small (only 55 total randomized participants across 3 arms) and the two primary analysis methods gave discordant significance results (NRI missed, LOCF met), which per the definitions caps this at moderate under both the underpowered-n and mixed/unclear-primary-result tests.
Next expected readout: June 2027 · NCT06045754 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) (met)
Result source: NCT02499783
Hemay007
Developed by Tianjin Hemay Pharmaceutical
NCT02603185 · Phase 1 · status unknown
This is a randomized, double-blind, placebo-controlled early-phase safety and pharmacokinetics study conducted in healthy volunteers rather than in patients with the target condition, with adverse-event monitoring as its primary endpoint rather than a measure of disease benefit. No results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "Adverse events assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | Hemay007 |
|---|---|---|
| Clinical remission (induction) | 37.3% vs 6.8%+30.5 vs placeboNCT024997831 other result
| —Not reported |
| Endoscopic response (induction) | —Trial running · NCT05040464 | —Not reported |
| Clinical remission (maintenance) | 47.4% vs 33.3%+14.1 vs placeboNCT0005549711 other results
| —Not reported |
| Endoscopic response (maintenance) | —Trial running · NCT05040464 | —Not reported |
Clinical remission (induction)
- adalimumab
- 37.3% vs 6.8%+30.5 vs placeboNCT02499783
1 other result
- 46.9% vs 27.7% NCT00348283
- Hemay007
- —Not reported
Endoscopic response (induction)
- adalimumab
- —Trial running · NCT05040464
- Hemay007
- —Not reported
Clinical remission (maintenance)
- adalimumab
- 47.4% vs 33.3%+14.1 vs placeboNCT00055497
11 other results
- 66.7% vs 33.3% NCT00055497
- 78.9% vs 44.4% NCT00055497
- 83.3% vs 44.4% NCT00055497
- 38.1% vs 9.1% NCT00445432
- 36.3% vs 38.9% NCT00055497
- 40.2% vs 38.9% NCT00055497
- 32.8% vs 9.2% NCT00348283
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- Hemay007
- —Not reported
Endoscopic response (maintenance)
- adalimumab
- —Trial running · NCT05040464
- Hemay007
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Hemay007: no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab: 4 of 4 rows · Hemay007: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab |
|---|---|
| Dropout rate | —40 mg every other weeka NCT00055497 · Phase 3 show 34 more results15.8%40 mg every other week NCT00055497 · Phase 3 11.1%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 40.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 48.5% NCT00195715 · Phase 3 16.9%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.4% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 6.8%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 6.8%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 21.4% NCT02185014 · Phase 3 · monotherapy 61% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 60%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 34.4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 35.7%80 mg NCT01958827 · Phase 3 · monotherapy 16.4%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 36% NCT02148718 · Phase 4 · registry result, not featured evidence 26.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 26.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —40 mg every other weeka NCT00055497 · Phase 3 show 34 more results5.3%40 mg every other week NCT00055497 · Phase 3 5.6%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 12.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 15.7% NCT00195715 · Phase 3 6%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 1.5% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 3.9%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 2.4%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 7.1% NCT02185014 · Phase 3 · monotherapy 8% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 21.9%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 10.7%80 mg NCT01958827 · Phase 3 · monotherapy 10.9%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination — NCT02148718 · Phase 4 · registry result, not featured evidence 20%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 20%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.3%40 mg every other weeka NCT00055497 · Phase 3 show 34 more results—40 mg every other week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 0%40 mg every week NCT00055497 · Phase 3 16.7%40 mg NCT00055497 · Phase 3 2%160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 38.1% NCT00195715 · Phase 3 —40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 14.8% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.5%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 4.9%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy 4.6%Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy 6.4%Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 10.7% NCT02185014 · Phase 3 · monotherapy 48% NCT00686374 · Phase 3 · monotherapy 23.7%40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20%20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 8%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 40.6%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 28.6%80 mg NCT01958827 · Phase 3 · monotherapy —40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 2.3% NCT02148718 · Phase 4 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 7.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 14.3%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 40 mg every other weeka nasopharyngitis 26.3% (placebo 38.9%) crohn's disease aggravated 21.1% (placebo 27.8%) sinusitis 21.1% (placebo 5.6%) NCT00055497 · Phase 3 show 28 more results40 mg every week crohn's disease aggravated 11.1% (placebo 27.8%) dizziness (excl vertigo) 11.1% (placebo 5.6%) nasopharyngitis 11.1% (placebo 38.9%) NCT00055497 · Phase 3 40 mg crohn's disease aggravated 17.6% (placebo 27.8%) nasopharyngitis 16.7% (placebo 38.9%) headache 14% (placebo 11.1%) NCT00055497 · Phase 3 160/80 mg white blood cell count decreased 5.9% (placebo 1%) cough 4.9% (placebo 0%) dizziness 3.9% (placebo 0%) NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg every other week or every week headache 18.9% nasopharyngitis 14.4% arthralgia 7.6% NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 crohn's disease 23.4% (placebo 29.2%) headache 14.1% (placebo 9.2%) nasopharyngitis 14.1% (placebo 12.3%) NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 viral upper respiratory tract infection 39% headache 37% upper respiratory tract infection 31% NCT00686374 · Phase 3 · monotherapy 40 mg or 20 mg every other week headache 17.2% crohn's disease 11.8% nausea 10.8% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20 mg or 10 mg every other week headache 21.1% crohn's disease 15.8% nasopharyngitis 11.6% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg Eow nasopharyngitis 56% (placebo 12%) rhinorrhoea 16% (placebo 0%) adverse drug reaction 12% (placebo 4%) NCT00445432 · Phase 2/3 · monotherapy 40 mg Eow nasopharyngitis 71.9% (placebo 12%) adverse drug reaction 18.8% (placebo 4%) iron deficiency anaemia 18.8% (placebo 0%) NCT00445432 · Phase 2/3 · monotherapy 160 mg/80 mg + 40/40 mg adverse drug reaction 11.1% (placebo 4.3%) application site swelling 11.1% (placebo 0%) blood creatine phosphokinase (at investigator's discretion) 11.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 160 mg/80 mg headache 9.1% (placebo 4.3%) upper respiratory tract infection 9.1% (placebo 4.3%) abdominal distension 6.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80/40 mg + 40/40 mg headache 16.7% (placebo 4.3%) abdominal distension 8.3% (placebo 0%) abdominal pain 8.3% (placebo 4.3%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80 mg/40 mg injection site reaction 8.8% (placebo 8.7%) malaise 8.8% (placebo 0%) rhinorrhoea 8.8% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 40 mg every other week crohn's disease 16.1% abdominal pain 7.6% injection site reaction 7.6% NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) arthralgia 18.2% crohn's disease 16.4% nasopharyngitis 10.9% NCT02764762 · Phase 4 · registry result, not featured evidence · combination vomiting 7% abdominal mass 5.8% arthralgia 4.7% NCT02148718 · Phase 4 · registry result, not featured evidence Low Induction Dose leukopenia 20% pyrexia 13.3% arthralgia 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Low Induction Dose leukopenia 15.4% animal bite 7.7% aphthous stomatitis 7.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose alanine aminotransferase increased 13.3% aspartate aminotransferase increased 13.3% abdominal pain 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose mycobacterium tuberculosis complex test positive 14.3% aspartate aminotransferase increased 7.1% asthenia 7.1% NCT02015793 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 11 more results
show 80 more results
show 11 more results
show 11 more results
show 6 more results
show 1 more result
show 4 more results
+ 62 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · Hemay007's landscape